HM Payson & Co. maintained its position in shares of Eli Lilly and Co. (NYSE:LLY) during the third quarter, Holdings Channel reports. The firm owned 29,576 shares of the company’s stock at the end of the third quarter. HM Payson & Co.’s holdings in Eli Lilly and were worth $2,374,000 at the end of the most recent quarter.
Other institutional investors also recently modified their holdings of the company. Franklin Resources Inc. boosted its position in shares of Eli Lilly and by 2.5% in the second quarter. Franklin Resources Inc. now owns 28,430,876 shares of the company’s stock worth $2,238,939,000 after buying an additional 685,898 shares in the last quarter. BlackRock Institutional Trust Company N.A. boosted its position in shares of Eli Lilly and by 1.1% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 26,674,046 shares of the company’s stock worth $2,100,581,000 after buying an additional 289,681 shares in the last quarter. BlackRock Fund Advisors boosted its position in shares of Eli Lilly and by 2.5% in the third quarter. BlackRock Fund Advisors now owns 17,629,570 shares of the company’s stock worth $1,414,949,000 after buying an additional 423,179 shares in the last quarter. Bank of New York Mellon Corp boosted its position in shares of Eli Lilly and by 6.9% in the third quarter. Bank of New York Mellon Corp now owns 15,164,215 shares of the company’s stock worth $1,217,080,000 after buying an additional 984,404 shares in the last quarter. Finally, Massachusetts Financial Services Co. MA boosted its position in shares of Eli Lilly and by 6.4% in the second quarter. Massachusetts Financial Services Co. MA now owns 11,913,007 shares of the company’s stock worth $938,150,000 after buying an additional 715,620 shares in the last quarter. 73.90% of the stock is currently owned by institutional investors and hedge funds.
Eli Lilly and Co. (NYSE:LLY) traded down 0.89% during trading on Thursday, reaching $76.84. 4,438,371 shares of the company were exchanged. The firm has a 50-day moving average of $72.28 and a 200-day moving average of $77.17. The firm has a market cap of $81.27 billion, a price-to-earnings ratio of 33.42 and a beta of 0.25. Eli Lilly and Co. has a 52-week low of $64.18 and a 52-week high of $83.79.
Eli Lilly and (NYSE:LLY) last released its quarterly earnings results on Tuesday, October 25th. The company reported $0.88 EPS for the quarter, missing the Zacks’ consensus estimate of $0.96 by $0.08. The firm earned $5.19 billion during the quarter, compared to analyst estimates of $4.23 billion. Eli Lilly and had a net margin of 11.73% and a return on equity of 23.71%. Eli Lilly and’s quarterly revenue was up 4.7% on a year-over-year basis. During the same quarter last year, the firm earned $0.89 earnings per share. On average, equities analysts forecast that Eli Lilly and Co. will post $3.54 EPS for the current year.
The business also recently announced a quarterly dividend, which will be paid on Friday, March 10th. Stockholders of record on Wednesday, February 15th will be given a dividend of $0.52 per share. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.68%. This is a positive change from Eli Lilly and’s previous quarterly dividend of $0.51. The ex-dividend date of this dividend is Monday, February 13th. Eli Lilly and’s dividend payout ratio is presently 88.70%.
A number of equities analysts have issued reports on LLY shares. Goldman Sachs Group Inc. raised shares of Eli Lilly and from a “neutral” rating to a “buy” rating and raised their target price for the stock from $89.00 to $95.00 in a report on Tuesday, September 27th. BMO Capital Markets reissued an “outperform” rating and issued a $94.00 target price on shares of Eli Lilly and in a report on Tuesday, September 27th. Zacks Investment Research raised shares of Eli Lilly and from a “hold” rating to a “buy” rating and set a $89.00 target price on the stock in a report on Tuesday, September 27th. Leerink Swann reissued a “buy” rating and issued a $103.00 target price on shares of Eli Lilly and in a report on Sunday, October 9th. Finally, Societe Generale restated a “hold” rating and issued a $78.00 price target on shares of Eli Lilly and in a research note on Thursday, October 27th. Two research analysts have rated the stock with a sell rating, three have issued a hold rating, twelve have given a buy rating and one has given a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus price target of $88.24.
In other news, SVP Susan Mahony sold 20,242 shares of the company’s stock in a transaction that occurred on Friday, December 16th. The shares were sold at an average price of $72.65, for a total transaction of $1,470,581.30. Following the transaction, the senior vice president now directly owns 67,802 shares in the company, valued at $4,925,815.30. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director R David Hoover bought 500 shares of Eli Lilly and stock in a transaction dated Friday, December 16th. The shares were bought at an average price of $71.85 per share, for a total transaction of $35,925.00. Following the completion of the transaction, the director now directly owns 33,504 shares of the company’s stock, valued at approximately $2,407,262.40. The disclosure for this purchase can be found here. Insiders have sold 222,335 shares of company stock worth $16,160,689 over the last quarter. 0.20% of the stock is owned by company insiders.
About Eli Lilly and
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Co. (NYSE:LLY).